Document is current
Any future updates will be listed below
-
Authors
Lim, Darren Wan-Teck https://orcid.org/0000-0002-4655-0206
Kao, Hsiang-Fong
Suteja, Lisda https://orcid.org/0000-0002-4548-2766
Li, Constance H.
Quah, Hong Sheng https://orcid.org/0000-0001-8430-8528
Tan, Daniel Shao-Weng https://orcid.org/0000-0002-6514-6786
Tan, Sze-Huey https://orcid.org/0000-0002-3089-7379
Tan, Eng-Huat
Tan, Wan-Ling
Lee, Justina Nadia
Wee, Felicia Yu-Ting
Jain, Amit
Goh, Boon-Cher
Chua, Melvin L. K. https://orcid.org/0000-0002-1648-1473
Liao, Bin-Chi
Ng, Quan Sing
Hong, Ruey-Long
Ang, Mei-Kim
Yeong, Joe Poh-Sheng https://orcid.org/0000-0002-6674-7153
Iyer, N. Gopalakrishna https://orcid.org/0000-0002-8812-6219
-
Funding
Funding for this research was provided by:
MOH | National Medical Research Council (NMRC/CSA/001/2016, MOH-000325-00, NMRC/CSA-INV/0025/2017, MOH-000375-01, NMRC/CSA/MOH-CSAINV19NOV-0005)
- License Information
-
More Information
Article History
Received: 15 July 2022
Accepted: 2 May 2023
First Online: 15 May 2023
Competing interests
: NGI sits on the Scientific Advisory Boards of PairX Therapeutics, VerImmune and Vivo Surgical, and has received honoraria/funding from Merck, Kalbe Biotech and Agilent, all of which are outside the scope of this submitted work. D.W.T.L. has received research funding from Bristol-Myers Squibb through institution. He has also received honoraria/travel support from Merck, Roche, Boehringer-Ingelheim, Taiho Pharmaceuticals, Pfizer, Novartis, and Eisai which are outside the scope of the submitted work. The remaining authors declare no other competing interests.
